The increasing prevalence of neurological disorders, such as cerebral aneurysms, ischemic strokes, and arteriovenous malformations (AVMs), is the key factor…
With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA…